Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021
Abstract Background Biologics are therapeutic options for the management of moderate−severe plaque psoriasis. Some patients need to switch biologic treatment to achieve satisfactory outcomes, which might have a considerable economic impact. Objectives We assessed the characteristics and switch rates...
        Saved in:
      
    
          | Main Authors: | Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Wiley
    
        2024-12-01 | 
| Series: | JEADV Clinical Practice | 
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.512 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
Similar Items
- 
                
                    Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab        
                          
 by: Liz S. Gea, et al.
 Published: (2024-10-01)
- 
                
                    Evaluation of the efficacy and safety of cold laser (Diode 808 nm) therapy in the treatment of localized plaque psoriasis: clinical, dermoscopic and ultrastructural study        
                          
 by: Reham L. Gohar, et al.
 Published: (2024-05-01)
- 
                
                    A Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Phase 2 Study Evaluating the Efficacy and Safety of GN-037 Cream in Patients with Mild-to-Moderate Plaque Psoriasis        
                          
 by: Burhan Engin, et al.
 Published: (2024-11-01)
- 
                
                    Rare Association of Dermatitis Herpetiformis and Chronic Plaque Psoriasis        
                          
 by: Fatima Ezzahraa Chekairi, et al.
 Published: (2024-12-01)
- 
                
                    Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis        
                          
 by: April W. Armstrong, et al.
 Published: (2024-10-01)
 
       